Cargando…

COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study

OBJECTIVE: To describe the rate and type of adverse effects (AEs) and the frequency of disease flares after COVID-19 vaccination and to assess the reasons for vaccination hesitancy (non-vaccination) in SRD patients. METHODS: Telephone interviews were conducted of SRD patients consecutively enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fragoulis, George E., Bournia, Vassiliki-Kalliopi, Mavrea, Eugenia, Evangelatos, Gerasimos, Fragiadaki, Kalliopi, Karamanakos, Anastasios, Kravariti, Eyrydiki, Laskari, Katerina, Panopoulos, Stylianos, Pappa, Maria, Mitsikostas, Dimos D., Tektonidou, Maria G., Vassilopoulos, Dimitrios, Sfikakis, Petros P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Observational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569844/ https://www.ncbi.nlm.nih.gov/pubmed/34739573 http://dx.doi.org/10.1007/s00296-021-05039-3

Ejemplares similares

Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic
por: Fragoulis, George E., et al.
Publicado: (2020)

Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study
por: Fragoulis, George E., et al.
Publicado: (2021)

Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease
por: Bournia, Vasiliki-Kalliopi, et al.
Publicado: (2020)

Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus
por: Fragoulis, George E., et al.
Publicado: (2020)

Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice
por: Gialouri, Chrysoula G., et al.
Publicado: (2022)

Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases
por: Papagoras, Charalampos, et al.
Publicado: (2023)

Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers
por: Mitsikostas, Dimos D., et al.
Publicado: (2021)

Chronological Age and DNA Damage Accumulation in Blood Mononuclear Cells: A Linear Association in Healthy Humans after 50 Years of Age
por: Vlachogiannis, Nikolaos I., et al.
Publicado: (2023)

Different systemic rheumatic diseases as risk factors for COVID-19-related mortality
por: Fragoulis, George E., et al.
Publicado: (2022)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
por: Spanou, Ioanna, et al.
Publicado: (2019)

Late-Onset Psoriatic Arthritis: Are There Any Distinct Characteristics? A Retrospective Cohort Data Analysis
por: Gialouri, Chrysoula G., et al.
Publicado: (2023)

Cardiac Catheterization versus Echocardiography for Monitoring Pulmonary Pressure: A Prospective Study in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
por: Bournia, Vasiliki Kalliopi, et al.
Publicado: (2020)

All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015–2019
por: Bournia, Vasiliki-Kalliopi, et al.
Publicado: (2021)

Higher frequency but similar recurrence rate of uveitis episodes in axial spondylarthritis compared to psoriatic arthritis. A multicentre retrospective study
por: Kougkas, Nikolaos, et al.
Publicado: (2023)

Editorial: Nocebo Effects and Their Influence on Clinical Trials and Practice: Modulating Factors in Healthy and Pathological Conditions
por: Amanzio, Martina, et al.
Publicado: (2020)

Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study
por: Bournia, Vasiliki-Kalliopi, et al.
Publicado: (2022)

European Headache Federation recommendations for placebo and nocebo terminology
por: Mitsikostas, Dimos D., et al.
Publicado: (2020)

Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE
por: Panopoulos, Stylianos, et al.
Publicado: (2023)

A Case of Microscopic Polyangiitis Presenting as Cranial Giant Cell Arteritis
por: Evangelatos, Gerasimos, et al.
Publicado: (2020)

Microwave Radiometry for the Diagnosis and Monitoring of Inflammatory Arthritis
por: Laskari, Katerina, et al.
Publicado: (2023)

Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
por: Gialouri, Chrysoula G., et al.
Publicado: (2022)

EHMTI-0331. Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation
por: Deligianni, C, et al.
Publicado: (2014)

Cardiovascular Magnetic Resonance Identifies High-Risk Systemic Sclerosis Patients with Normal Echocardiograms and Provides Incremental Prognostic Value
por: Markousis-Mavrogenis, George, et al.
Publicado: (2019)

Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
por: Evangelatos, Gerasimos, et al.
Publicado: (2020)

Musculoskeletal Complications of Celiac Disease: A Case-Based Review
por: Evangelatos, Gerasimos, et al.
Publicado: (2023)

Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report
por: Evangelatos, Gerasimos, et al.
Publicado: (2021)

Adenosine-to-inosine RNA editing contributes to type I interferon responses in systemic sclerosis
por: Vlachogiannis, Nikolaos I., et al.
Publicado: (2021)

The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice
por: Kravvariti, Evrydiki, et al.
Publicado: (2019)

Vaccine hesitancy prospectively predicts nocebo side-effects following COVID-19 vaccination
por: Hoffman, Yaakov S. G., et al.
Publicado: (2022)

Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
por: Panopoulos, S., et al.
Publicado: (2020)

Placebo – Nocebo
por: Mosser, Astrid
Publicado: (2022)

The influence of anti-cyclic citrullinated peptide on anticentromere antibody-positive rheumatoid arthritis patients: authors' response
por: Vlachoyiannopoulos, Panayiotis G, et al.
Publicado: (2010)

The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era
por: Evangelatos, Gerasimos, et al.
Publicado: (2022)

Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study
por: Panopoulos, Stylianos, et al.
Publicado: (2018)

The nocebo effect of drugs
por: Planès, Sara, et al.
Publicado: (2016)

Information About the Optimism of a Placebo/Nocebo Provider and Placebo/Nocebo Side Effects
por: Schlintl, Carina, et al.
Publicado: (2021)

Susceptibility to Nocebo Hyperalgesia, Dispositional Optimism, and Trait Anxiety as Predictors of Nocebo Hyperalgesia Reduction
por: Karacaoglu, Merve, et al.
Publicado: (2023)

Intertoe Squamous Cell Carcinoma Developed in a Patient with Rheumatoid Arthritis under Etanercept Therapy
por: Rallis, Efstathios, et al.
Publicado: (2015)

Nocebo effects in the treatment of endometriosis
por: Thiel, Peter, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rt2oq181qr8l40jrbetqsrjce2